In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.7326/acpj202002180-018
PubMed Identifier: 32066151
Publication URI: http://europepmc.org/abstract/MED/32066151
Type: Journal Article/Review
Volume: 172
Parent Publication: Annals of internal medicine
Issue: 4
ISSN: 0003-4819